RNA

Healthcare Biotechnology

Atrium Therapeutics, Inc.

$7.84

-0.16 -2.00% today

Price History

Not enough data

Key Stats

Market Cap

134.11M

Avg Volume

251,370

EPS

-$5.44

52W High

$16.77

52W Low

$7.68

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-0.97

P/B Ratio

0.63

P/S Ratio

3.74

EV/EBITDA

1.87

EV/Revenue

-3.58

Margins

Gross Margin (56.4%)

Operating Margin (752.9%)

Net Margin (184.1%)

EBITDA Margin (191.2%)

Growth & Returns

Revenue Growth (YoY)

(21.9%)

Liquidity & Leverage

Current Ratio

8.73

Quick Ratio

8.38

Debt / Equity

0.01

Total Cash

263.90M

Total Debt

1.68M

About

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.

atriumtherapeutics.com